ACTRN12614000007639
Completed
Phase 3
Improved treatment of Type 2 Diabetes by improving the splenic function and intestinal tract using ANIVINA, a novel drug composition based on naturally occurring bioactive compounds
guyen Van Toan0 sites94 target enrollmentJanuary 3, 2014
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Splenic and gastro intestinal disorder in Type 2 Diabetes Mellitus
- Sponsor
- guyen Van Toan
- Enrollment
- 94
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •All participated patients aged between 52\-85 years old, diagnosed with type 2 diabetes mellitus were informed about the purposes, methods and intended uses of the research. They were informed about what participation will involve and the risks as well as potential benefits explained. Moreover. the participants were allowed to withdraw themselves from participation at any time and for any reason without disadvantage and all information as well as data obtained about participants were confidential
Exclusion Criteria
- •Out of age range of 52\-85
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
Treating To Target in Type 2 diabetesType 2 diabetesNutritional, Metabolic, EndocrineNon-insulin-dependent diabetes mellitusISRCTN51125379ovo Nordisk Limited (UK)700
Active, not recruiting
Not Applicable
OPTIMISATION OF INSULIN TREATMENT OF TYPE 2 DIABETES MELLITUS BY TELECARE ASSISTANCE FOR SELF MONITORING OF BLOOD GLUCOSE ELEONOR STUDYTYPE 2 DIABETES MELLITUSMedDRA version: 6.1Level: HLTClassification code 10012602EUCTR2004-002731-62-ITAVENTIS PHARMA S.P.A.480
Completed
Not Applicable
Salutogenic intervention for Diabetes Type 2Diabetes Mellitus Type 2 (T2DM)NL-OMON27447Wageningen University, Edema-Steernberg Foundation56
Completed
Not Applicable
The control and prevention of type 2 diabetes by the inhibition of adipose tissue inflammation through DiacereiPatients aged 40â€65 years who had type 2 Diabetes for at least 2 years since diagnosis with a glycated haemoglobin (HbA1c) level of 7.5%â€10%type 2 Diabetes who had inadequate glycaemic controlTCTR20200820004/A35
Active, not recruiting
Phase 1
The DIAMOND for the Treatment of Type 2 Diabetes: Can Blood Triglycerides level be the predictor for therapy efficiency?Diabetes type 2 not controlled by oral medication.Therapeutic area: Body processes [G] - Physiological processes [G07]EUCTR2013-001003-36-ATMetacure Ltd.45